Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Preterm prelabour rupture of membranes.

BIBLIOGRAPHIC SOURCE(S)

  • Royal College of Obstetricians and Gynaecologists (RCOG). Preterm prelabour rupture of membranes. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2006 Nov. 11 p. (Guideline; no. 44). [66 references]

GUIDELINE STATUS

This is the current release of the guideline.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

In addition to these evidence-based recommendations, the guideline development group also identifies points of best clinical practice in the original guideline document.

Levels of evidence (Ia-IV) and grading of recommendations (A-C) are defined at the end of the "Major Recommendations" field.

How Is the Diagnosis of Preterm Prelabour Rupture of Membranes (PPROM) Best Achieved?

B - The diagnosis of spontaneous rupture of the membranes is best achieved by maternal history followed by a sterile speculum examination.

C - Ultrasound examination is useful in some cases to help confirm the diagnosis.

C - Digital examination should be avoided where PPROM is suspected.

What Antenatal Tests Should Be Performed?

C - Fetal monitoring using cardiotocography should be considered where regular fetal surveillance is required.

B - Biophysical profile scoring or Doppler velocimetry should not be considered as first-line surveillance or diagnostic tests for fetal infection.

The criteria for the diagnosis of clinical chorioamnionitis include maternal pyrexia, tachycardia, leucocytosis, uterine tenderness, offensive vaginal discharge, and fetal tachycardia. During inpatient observation, the woman should be regularly examined for such signs of intrauterine infection and an abnormal parameter or a combination of them may indicate intrauterine infection. The frequency of maternal temperature, pulse and fetal heart rate auscultation should be between 4 hours and 8 hours.

What is the Role of Amniocentesis?

B - Routine amniocentesis is not recommended for women with PPROM.

Management

Are Prophylactic Antibiotics Recommended?

A - Erythromycin (250 mg orally 6 hourly) should be given for 10 days following the diagnosis of PPROM.

A - Co-amoxiclav is not recommended for women with PPROM because of concerns about necrotising enterocolitis.

If group B streptococcus is isolated in cases of PPROM, antibiotics should be given in line with the recommendation for routine intrapartum prophylaxis in the National Guideline Clearinghouse (NGC) summary of the Royal College of Obstetricians and Gynaecologists (RCOG) Green-top Guideline No. 36: Prevention of Early Onset Neonatal Group B Streptococcal Disease.

What is the Role of Antenatal Corticosteroids?

A - Antenatal corticosteroids should be administered in women with PPROM.

Tocolysis: Should Tocolytic Agents Be Used?

A - Prophylactic tocolysis in women with PPROM without uterine activity is not recommended.

Amnioinfusion

Should Amnioinfusion in Labour Be Carried Out?

A - Transvaginal amnioinfusion in labour is not recommended for women with preterm rupture of membranes.

B - Transabdominal amnioinfusion is not recommended as a method of preventing pulmonary hypoplasia in very preterm PPROM.

Use of Fibrin Glue

What is the Role of Fibrin Glue in the Sealing of Chorioamniotic Membranes to Prevent Pulmonary Hypoplasia?

B - Fibrin sealants are not recommended as routine treatment for second-trimester oligohydramnios caused by PPROM.

Outpatient Monitoring

Can Patients Be Monitored at Home?

B - Women should be considered for outpatient monitoring of PPROM only after rigorous individual selection by a consultant obstetrician.

There are insufficient data to make recommendations of home, daycare and outpatient monitoring rather than continued hospital admission in women with PPROM. It would be considered reasonable to maintain the woman in hospital for at least 48 hours before a decision is made to allow her to go home. This method of management should be individualised and restricted to certain groups of women. Women should be instructed to take regular temperature recordings at home every 12 hours or to be aware of the symptoms associated with infection. (Evidence level III)

Delivery of the Fetus

When Is the Appropriate Time to Deliver?

B - Delivery should be considered at 34 weeks of gestation.

B - Where expectant management is considered beyond 34 weeks of gestation, women should be counselled about the increased risk of chorioamnionitis and its consequences versus the decreased risk of serious respiratory problems in the neonate, admission for neonatal intensive care, and caesarean section.

Definitions:

Grading of Recommendations

Grade A - Requires at least one randomised controlled trial as part of a body of literature of overall good quality and consistency addressing the specific recommendation. (Evidence levels Ia, Ib)

Grade B - Requires the availability of well controlled clinical studies but no randomised clinical trials on the topic of recommendations. (Evidence levels IIa, IIb, III)

Grade C - Requires evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities. Indicates an absence of directly applicable clinical studies of good quality. (Evidence level IV)

Levels of Evidence

Ia: Evidence obtained from meta-analyses of randomised controlled trials

Ib: Evidence obtained from at least one randomised controlled trial

IIa: Evidence obtained from at least one well-designed controlled study without randomisation

IIb: Evidence obtained from at least one other type of well-designed quasi-experimental study

III: Evidence obtained from well-designed non-experimental descriptive studies, such as comparative studies, correlation studies, and case studies

IV: Evidence obtained from expert committee reports or opinions and/or clinical experience of respected authorities

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is identified and graded for each recommendation (see "Major Recommendations" field).

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • Royal College of Obstetricians and Gynaecologists (RCOG). Preterm prelabour rupture of membranes. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2006 Nov. 11 p. (Guideline; no. 44). [66 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2006 Nov

GUIDELINE DEVELOPER(S)

Royal College of Obstetricians and Gynaecologists - Medical Specialty Society

SOURCE(S) OF FUNDING

Royal College of Obstetricians and Gynaecologists

GUIDELINE COMMITTEE

Guidelines and Audit Committee of the Royal College of Obstetricians and Gynaecologists

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Author: Mr SGM Carroll, FRCOG, Dublin, Ireland

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Guideline authors are required to complete a "declaration of interests" form.

GUIDELINE STATUS

This is the current release of the guideline.

GUIDELINE AVAILABILITY

Electronic copies: Available in Portable Document Format (PDF) from the Royal College of Obstetricians and Gynaecologists (RCOG) Web site.

Print copies: Available from the Royal College of Obstetricians and Gynaecologists (RCOG) Bookshop, 27 Sussex Place, Regent's Park, London NW1 4RG; Telephone: +44 020 7772 6276; Fax, +44 020 7772 5991; e-mail: bookshop@rcog.org.uk. A listing and order form are available from the RCOG Web site.

AVAILABILITY OF COMPANION DOCUMENTS

The following are available:

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI Institute on November 30, 2007.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo